Beta Drugs is one of the leading players in the domestic oncology space

Discussion in 'Latest Brokerage Stock Buy-Sell Reports' started by Vidhi Khanna, Sep 9, 2023.

  1. Vidhi Khanna

    Vidhi Khanna Active Member Staff Member

    Joined:
    Mar 19, 2015
    Messages:
    579
    Likes Received:
    55
    BETA DRUGS is well placed to capitalise on growth opportunities in the oncology drugs segment. It has a healthy Balance Sheet. Average RoE in past three years is 24%. P/E ratio is 15x. Revenue/earnings CAGR of 26%/33% over FY23–26 is expected. TP is Rs 1325

    Download research report

    [​IMG]
     
Loading...